dipyridamole has been researched along with Atherogenesis in 13 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We defined the time course and magnitude of changes of plasma eNOS and oxLDL after Aggrenox or aspirin in post-stroke patients." | 9.15 | Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy. ( Eisert, C; Fong, A; Hanley, D; Sani, Y; Schevchuck, A; Serebruany, V, 2011) |
| "To identify the presence of subclinical atherosclerosis in patients with psoriatic arthritis (PsA) and healthy controls using intima-media thickness (IMT), coronary flow reserve (CFR), and the plasma concentration of asymmetric dimethylarginine (ADMA), to evaluate the correlations among ADMA, IMT, and CFR." | 7.77 | Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. ( Atzeni, F; Battellino, M; Boccassini, L; De Gennaro Colonna, V; Gianturco, L; Marchesoni, A; Sarzi-Puttini, P; Sitia, S; Tomasoni, L; Turiel, M, 2011) |
| "We selected parameters (fibrinogen, micro/macroalbuminuria, ateroma in carotid artery bed) that were significantly associated with stress myocardial SPECT result." | 7.73 | [The meaning of the combination of fibrinogen, micro/macroalbuminuria and atheromatosis in the carotid bloodstream for the evaluation of the abnormal finding of the stress myocardial SPECT in the asymptomatic 2nd type diabetic patients]. ( Holá, D; Pálová, S; Zamrazil, V, 2006) |
| " We defined the time course and magnitude of changes of plasma eNOS and oxLDL after Aggrenox or aspirin in post-stroke patients." | 5.15 | Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy. ( Eisert, C; Fong, A; Hanley, D; Sani, Y; Schevchuck, A; Serebruany, V, 2011) |
| "Recent trials of antiplatelet therapy for stroke prevention indicate that the combination of clopidogrel (75 mg/d) plus low-dose aspirin (75-162 mg/d) was not more effective than low-dose aspirin alone in the long-term prevention of major vascular events among patients at high risk of atherothrombotic events, nor was it more effective than oral anticoagulation in patients with atrial fibrillation." | 4.84 | Antiplatelet therapy for stroke prevention. ( Hankey, GJ, 2007) |
| "To identify the presence of subclinical atherosclerosis in patients with psoriatic arthritis (PsA) and healthy controls using intima-media thickness (IMT), coronary flow reserve (CFR), and the plasma concentration of asymmetric dimethylarginine (ADMA), to evaluate the correlations among ADMA, IMT, and CFR." | 3.77 | Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. ( Atzeni, F; Battellino, M; Boccassini, L; De Gennaro Colonna, V; Gianturco, L; Marchesoni, A; Sarzi-Puttini, P; Sitia, S; Tomasoni, L; Turiel, M, 2011) |
| "We selected parameters (fibrinogen, micro/macroalbuminuria, ateroma in carotid artery bed) that were significantly associated with stress myocardial SPECT result." | 3.73 | [The meaning of the combination of fibrinogen, micro/macroalbuminuria and atheromatosis in the carotid bloodstream for the evaluation of the abnormal finding of the stress myocardial SPECT in the asymptomatic 2nd type diabetic patients]. ( Holá, D; Pálová, S; Zamrazil, V, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tuttolomondo, A | 1 |
| Pecoraro, R | 1 |
| Di Raimondo, D | 1 |
| Arnao, V | 1 |
| Clemente, G | 1 |
| Della Corte, V | 1 |
| Maida, C | 1 |
| Simonetta, I | 1 |
| Licata, G | 1 |
| Pinto, A | 1 |
| Alexandrov, AV | 1 |
| Alagona, P | 1 |
| Biller, J | 1 |
| Gomez, CR | 1 |
| Qureshi, AI | 1 |
| Arauz, A | 1 |
| Calleja, J | 1 |
| Vallejo, E | 1 |
| Quintero, L | 1 |
| De Caterina, R | 1 |
| Massaro, M | 1 |
| Scoditti, E | 1 |
| Annunziata Carluccio, M | 1 |
| Serebruany, V | 1 |
| Sani, Y | 1 |
| Eisert, C | 1 |
| Schevchuck, A | 1 |
| Fong, A | 1 |
| Hanley, D | 1 |
| Atzeni, F | 1 |
| Sarzi-Puttini, P | 1 |
| Sitia, S | 1 |
| Tomasoni, L | 1 |
| Gianturco, L | 1 |
| Battellino, M | 1 |
| Boccassini, L | 1 |
| De Gennaro Colonna, V | 1 |
| Marchesoni, A | 1 |
| Turiel, M | 1 |
| Schaper, W | 1 |
| Zamrazil, V | 1 |
| Pálová, S | 1 |
| Holá, D | 1 |
| Liao, JK | 1 |
| Meadows, TA | 1 |
| Bhatt, DL | 1 |
| Hankey, GJ | 1 |
8 reviews available for dipyridamole and Atherogenesis
| Article | Year |
|---|---|
Stroke subtypes and their possible implication in stroke prevention drug strategies.
Topics: Animals; Antihypertensive Agents; Aspirin; Atherosclerosis; Blood Pressure; Dipyridamole; Humans; Pl | 2013 |
Stroke and atherothrombosis: an update on the role of antiplatelet therapy.
Topics: Atherosclerosis; Delayed-Action Preparations; Dipyridamole; Embolism, Cholesterol; Humans; Platelet | 2008 |
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic; | 2009 |
Pharmacological modulation of vascular inflammation in atherothrombosis.
Topics: Atherosclerosis; Biomarkers; Dipyridamole; Endothelium; Humans; Inflammation Mediators; Models, Card | 2010 |
Dipyridamole, an underestimated vascular protective drug.
Topics: Adenosine; Angina Pectoris; Animals; Atherosclerosis; Coronary Circulation; Coronary Vessels; Dipyri | 2005 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Clinical aspects of platelet inhibitors and thrombus formation.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cilostazol; Clopidogrel; Dipyrid | 2007 |
Antiplatelet therapy for stroke prevention.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel | 2007 |
1 trial available for dipyridamole and Atherogenesis
| Article | Year |
|---|---|
Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Atherosclerosis; Biomarkers; Case-Control Studies; | 2011 |
4 other studies available for dipyridamole and Atherogenesis
| Article | Year |
|---|---|
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
Prevalence of silent myocardial ischemia in single and multiple lacunar infarcts and large vessel disease stroke.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Blood Vessels; Brain Infarction; Dipyridamole; Exer | 2010 |
Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis.
Topics: Adult; Aged; Arginine; Arthritis, Psoriatic; Atherosclerosis; Biomarkers; Carotid Artery, Common; Co | 2011 |
[The meaning of the combination of fibrinogen, micro/macroalbuminuria and atheromatosis in the carotid bloodstream for the evaluation of the abnormal finding of the stress myocardial SPECT in the asymptomatic 2nd type diabetic patients].
Topics: Albuminuria; Atherosclerosis; Carotid Arteries; Carotid Artery Diseases; Coronary Circulation; Coron | 2006 |